FasL-engineered biomaterials with immunomodulatory function
US11602547B2 · kind B2 · utility
0Cited by
7References
41Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 9, 2018 |
| Grant date | Mar 14, 2023 |
| Priority date | — |
| Expiry date | Mar 3, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N15/85
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described herein are FasL-engineered biomaterials, as well as methods of making and using such FasL-engineered biomaterials, such as for immunomodulation, such as for inducing immunosuppression and specific immune tolerance, such as for preventing or reducing the risks of rejection of cellular or tissue grafts and/or the treatment of autoimmune disorders such as Type I diabetes. In specific embodiments, the FasL-engineered biomaterials are biotinylated microgels bound to SA-FasL.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.